What is Car-T?

image


CAR T cell therapy is created by adding a new receptor (or hook) to a patient’s T cells. This receptor is called a chimeric antigen receptor, or CAR. Their body’s T cell with the CAR added is now called a CAR T cell.

The patient’s new CAR T cells are returned to their body through an infusion. The new CAR T cells may work within the body to find their match on specific cells, which include normal cells and cancer cells.

View

Approved Car-T cell

KYMRIAH®

manufacturing enterprise:  Novartis Pharma AG
Indication:  treatment used in patients up to 25 years old who have acute lymphoblastic leukemia (ALL) , It is also used in patients with non-Hodgkin lymphoma that has relapsed or is refractory after having at least two other kinds of treatment.
prices:  $475,000

Read More

YESCARTA

manufacturing enterprise:  Kite Pharma, Incorporated
Indication:  YESCARTA is a treatment for recurrent or refractory non-Hodgkin lymphoma in adults(including large B-cell lymphoma). Used in the case of failure to use at least two other treatments in the early stages.
prices:  $375,000

Read More

Learn more about China Car-T

image
3000
Car-T Cases

international patients in the area of Cancer

image
50000
Finest Doctors

here is a high level of competency

image
282
Clinical Trials

The number of clinical trials is less than that in the United States.

image
90%CR
Clinical Effect

The clinical effect of Car-T cell therapy is significant

patient story

Car-T News

ABOUT DOCOTOR

image
Daopei Lu

China key discipline leader

-Founder of Institute of Hematology, Peking University -Distinguished Professor at Peking University, Fudan University and Wuhan University

image
Peihua (Peggy) Lu, M.D

Clinical Professor

Leukemia, Multiple myeloma, Lymphoma, Aplastic anemia, acute and chronic myeloproliferative disease.

image
Luhua (Michael) Wang, M.D.

Clinical Professor

Leukemia, Lymphoma, Myeloma, Mantle Cell Lymphoma and Autoimmune diseases

image
Xian Zhang

Clinical Professor

Leukemia, Multiple myeloma, Lymphoma, Aplastic anemia, acute and chronic myeloproliferative disease

Car-T hospitals

Authoritative hospital gives you one-stop service

Indications of cart therapy

image 1
Diagnoses:

• Acute B-cell lymphoblastic leukemia
• B-cell lymphoma
• Multiple myeloma

image 2
Age:

from 6 month to 70 years old

image 3
Previous treatment results:

First- and second-line treatment has not led to a remission

Quick Apply for Loan